The 5-HT₃ receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal *c-fos* expression in the anaesthetised rat

C M Kozlowski, A Green, D Grundy, F M Boissonade, C Bountra

Abstract

Background—Noxious intestinal distention elicits a reflex depressor response in the sodium pentobarbitone anaesthetised rat, which can be used as an index of visceral nociception. 5-HT₃ receptor antagonists inhibit this reflex. Repeated colorectal distention (CRD) induces Fos like immunoreactivity (Fos-LI) in the rat spinal cord.

Aims—To examine the effect of the 5-HT₃ receptor antagonist alosetron on the depressor response to CRD, and on Fos expression in the lumbosacral spinal cord.

Methods—Male rats were anaesthetised with sodium pentobarbitone, and mean arterial blood pressure monitored during repeated colorectal balloon inflation before and after treatment with alosetron or saline. Rats anaesthetised with urethane and treated with alosetron or saline underwent a repeated CRD paradigm, after which the lumbosacral spinal cord was removed and processed for visualisation of Fos-LI.

Results—CRD elicited reproducible, volume dependent falls in arterial blood pressure, and repeated distention-effect curves were constructed. Alosetron (1–100 µg/kg intravenously) inhibited the depressor response to CRD in a dose related manner, with an ID₅₀ value of 3.0 µg/kg. Following repeated CRD, numbers of Fos-LI neurones were significantly increased to 1246 (total in 12 sections at 120 µm intervals from L6 to S1) compared with 49 in sham distended animals. Pre-treatment with alosetron (100 µg/kg) significantly reduced numbers of Fos-LI neurones to 479.8.

Conclusion—The 5-HT₃ receptor antagonist alosetron inhibits the depressor response to CRD in a potent and dose dependent manner. It also inhibits CRD induced Fos-LI in the spinal cord. These results suggest that 5-HT₃ receptors are involved in visceral nociceptive transmission, perhaps located on primary afferent or spinal neurones.

(Gut 2000;46:474–480)

In man, distention of the gastrointestinal tract elicits visceral pain, as well as sensations including fullness and discomfort.^{1,2} In healthy subjects, visceral pain occurs in response to potentially tissue damaging distention pressure; however, the irritable bowel syndrome (IBS) has been described as a hypersensitivity of the gut, as many patients show reduced thresholds to pain and associated sensations in response to rectal balloon distention, which is not due to altered compliance.^{3,4} Recent studies have shown that 5-HT₃ receptor antagonists may modify gut sensation in patients with IBS. Alosetron has been reported to reduce pain scores significantly, and to increase rectal compliance in patients with IBS.^{5–8} Granisetron has also been reported to reduce rectal sensitivity in patients with IBS⁹ although ondansetron seems to be ineffective at reducing pain scores in similar studies.^{10,11}

In animals, noxious intestinal distention elicits a range of pseudoaffective responses including vasomotor, visceromotor, and respiratory responses,^{12–14} which can be used as an index of visceral nociception. The vasomotor response consists of a transient increase or decrease in arterial blood pressure, which is dependent on state and type of anaesthesia.¹⁴ This reflex is abolished by neonatal or perineural capsaicin,^{15,16} and is blocked by morphine in a naloxone reversible manner.¹³ Noxious intestinal distention also elicits an aversive response in conscious rats, as measured in a passive avoidance paradigm.¹⁴ Thus, intestinal distention can be considered to be an appropriate stimulus for studies of visceral nociception.

The immediate early gene *c-fos* is expressed in discrete areas of the central nervous system following chemical (cyclophosphamide, acetic acid, formalin, capsaicin) or mechanical (distention, ligation) visceral stimulation.^{17–23} Repetitive colorectal distention (CRD) induces *c-fos* expression in rat spinal cord, the number of Fos-like immunoreactive neurones increasing with stimulus intensity.²⁴ Numbers of Fos-like immunoreactive nuclei are greatest in the lumbosacral spinal segments following CRD, which corresponds to afferent projection from the pelvic nerve.²⁵ Systemic morphine has been shown to attenuate *c-fos* expression in the rat

Neuroscience Unit,
GlaxoWellcome
Research and
Development,
Stevenage SG1 2NY,
UK

C M Kozlowski
A Green
C Bountra

Department of
Biomedical Science,
University of Sheffield,
Sheffield S10 2TN, UK
D Grundy

Department of Oral
and Maxillofacial
Surgery, School of
Clinical Dentistry,
University of Sheffield
F M Boissonade

Correspondence to:
Dr C M Kozlowski

Accepted for publication
9 September 1999

Keywords: colorectal distention; alosetron; Fos; 5-HT₃; spinal cord; pseudoaffective reflex

Abbreviations used in this paper: CRD, colorectal distention; Fos-LI, Fos-like immunoreactive; IBS, irritable bowel syndrome.

spinal cord following noxious colorectal distention.²⁶

In animal studies, a number of 5-HT₃ receptor antagonists have been reported to inhibit the vasomotor response to noxious intestinal distention.^{27–28} In the pentobarbitone anaesthetised rat, ondansetron, granisetron, and tropisetron have been shown to inhibit dose dependently volume related hypotensive responses that are also sensitive to inhibition by morphine, in a naloxone sensitive manner.²⁸ In the present study, we have extended these studies to investigate the effect of the potent and selective 5-HT₃ receptor antagonist alosetron,²⁹ and we also report the effect of alosetron on repetitive noxious CRD evoked spinal *c-fos* in the urethane anaesthetised rat. Thus we aim to establish a mechanism of action of 5-HT₃ receptors specific to visceral nociceptive neurotransmission. A preliminary account of this work has been presented in abstract form.³⁰

Methods

All experiments were performed using male Wistar rats (220–340 g) with food and water ad libitum. All procedures were carried out in accordance with “Principles of laboratory animal care” (NIH publication No. 85-23) and Home Office guidelines (Animals (Scientific Procedures) Act 1986).

COLORECTAL DISTENTION—DEPRESSOR RESPONSE

Twenty nine rats were anaesthetised with sodium pentobarbitone (60 mg/kg intraperitoneally; 3–5 mg/kg intravenously). The trachea, right external jugular vein, and carotid artery were cannulated. The carotid cannula was connected to a chart recorder via a blood pressure transducer for continuous measurement of blood pressure. Body temperature was kept constant at 36–37°C using a homeothermic blanket. A 1 cm long latex balloon was inserted intrarectally so that the tip of the balloon was 2 cm from the anal verge. The balloon was connected via a double barrelled cannula to a pressure transducer, and to a saline filled syringe for inflation/deflation of the balloon (the cannula was secured to the base of the tail with tape). The animals were left for 20 minutes, in order to obtain a stable recording baseline. The balloon was rapidly inflated with increasing volumes of saline (0.5–2.5 ml) for 30 seconds at five minute intervals and resultant blood pressure changes recorded. The value taken was the maximum decrease in mean arterial pressure obtained during the 30 second distention period. Three distention-response curves were constructed in this manner, allowing 10 minutes between successive curves. Alosetron (1–100 µg/kg) or saline was administered 10 minutes prior to commencement of the third curve. A single dose only was tested in each animal.

COLORECTAL DISTENTION—SPINAL *c-fos* EXPRESSION

A total of 19 rats in four groups were included in this study: control CRD with intravenous saline (n=5), alosetron (30 µg/kg; n=5), aloset-

ron (30 µg/kg; n=5), and sham distended (n=4). Rats were anaesthetised with urethane (1.5 g/kg intraperitoneally). The trachea was intubated and the right external jugular vein was cannulated for drug administration. A 4 cm long latex balloon was inserted intrarectally until the tip of the balloon was 5 cm from the anal verge. The balloon was connected via a cannula to a barostat (Bioengineering, GlaxoWellcome Research and Development), and was inflated to 80 mm Hg for 30 seconds, every two minutes for a total of 120 minutes. In control (sham distended) animals, the balloon was not inflated. Within 30 minutes following the end of the distention period, the rats were perfused intracardially with 150 ml phosphate buffered saline followed by 300 ml neutral buffered formalin (Pioneer Research Chemicals Ltd).

The lumbosacral spinal cord (L4–S2) was removed and postfixed in fresh fixative for four hours at 4°C, then transferred to 30% sucrose in 0.1 M phosphate buffer overnight, again at 4°C for cryoprotection. Sections (40 µm) were cut on a freezing microtome; every fourth section was collected. Sections were stained for Fos-like immunoreactivity using the avidin-biotin technique, following a method similar to that described previously by Boissonade *et al.*³¹ Briefly, following preincubation with 10% normal rabbit serum (NRS) diluted in phosphate buffered saline (PBS) containing 0.2% Triton (PBST) for one hour, sections were incubated in an antibody raised in sheep against Fos (anti-Fos polyclonal antibody, 1/5000, Genosys Biotechnologies Inc., Cambridge, UK; diluted in PBST containing 5% NRS) for 44–48 hours at 4°C. The sections were rinsed, and incubated for 30 minutes in a solution containing biotinylated rabbit antiserum IgG (1/300, 30 minutes; Vector Laboratories Inc., Burlingame, California, USA), then incubated with the avidin-biotin complex (Vectastain Elite kit, Vector Laboratories Inc.). The reaction product was visualised using diaminobenzidine solution containing H₂O₂ and nickel chloride (DAB substrate kit, Vector Laboratories Inc.); the sections were then mounted on gelatin coated glass slides, dehydrated, and coverslips applied. To assess antibody specificity, diluted Fos antibody was preincubated with Fos peptide (10 nmol/ml; Genosys; for 24 hours at 4°C) prior to the procedure above. In addition, incubation with the primary antibody was omitted for some sections. In either case, no significant staining was observed.

Numbers of Fos-like immunoreactive (Fos-LI) nuclei were counted in 12 consecutive sections across the L6–S1 border as identified by morphology; the total number of Fos-LI nuclei in 12 sections was used for subsequent data analysis. The grey matter was divided into four regions, similar to those described previously²⁶ for assessing regional distribution of Fos-LI nuclei (see fig 1). Images of the spinal sections were taken using an image analysis package (Leica Q600 running QWIN software; Leica UK Ltd, Milton Keynes, UK).

Figure 1 (A) Bilateral Fos-like immunoreactivity (Fos-LI) in a section of L6-S1 spinal cord following repeated (2 h, 80 mm Hg for 30 s every 120 s) colorectal distention. (B) Areas used to count regional Fos-LI: area 1, superficial laminae I and II; area 2, laminae III and IV; area 3, lateral laminae V-VII (intermediolateral horn) and lateral ventral horn; area 4, medial laminae V-VII and X, and medial ventral horn.

Figure 2 Colorectal distention (30 s every 5 min) evokes volume related decreases in mean arterial pressure which are highly reproducible ($n=4$).

COMPOUNDS

Alosetron (2,3,4,5 tetrahydro-5-methyl-2-[5-methyl-1-H-imidazol-4-yl-methyl]-1H-pyrido[4,3-b]indol-1-one maleate; GlaxoWellcome) was dissolved in saline (0.9%, wt/vol sodium chloride) and was administered intravenously 10 minutes prior to the onset of the test procedure in both experimental groups (600 μ l dose volume). Urethane was purchased from Sigma and dissolved in saline (33% wt/vol).

DATA AND STATISTICAL ANALYSIS

Results are given as mean (SEM) from n observations. For the depressor response experiments, the ID_{50} for alosetron was calculated as the dose required to inhibit the response to a 1.5 ml distention by 50% (geometric mean with 95% confidence limits), and statistical significance was determined using Student's paired t test. In the immunocytochemistry study, significance was determined using one way analysis of variance (ANOVA) followed by Dunnett's post hoc test for multiple comparisons. In both cases, $p<0.05$ was considered significant.

Results

DEPRESSOR RESPONSE

The pentobarbitone anaesthetised rats displayed a mean arterial blood pressure of 108.3 (6.1) mm Hg ($n=12$). CRD (0.5–2.5 ml) elicited volume dependent falls in mean arterial blood pressure which were rapid in onset, and persisted for the duration of the distention period, despite some reduction (10–15%) in intraballoon pressure, returning to control

Figure 3 Influence of alosetron (1–100 μ g/kg) on the hypotensive response to colorectal distention.

Figure 4 Alosetron reduces the number of Fos-like immunoreactive (Fos-LI) nuclei (in 12 sections across L6–S1) evoked following 2 h (80 mm Hg, for 30 s every 120 s) repeated colorectal distention. * $p < 0.05$, ** $p < 0.01$, significant reduction of Fos-LI.

values within two minutes after the distention was stopped. Some animals (26% in this study) did not display a depressor response to CRD; these animals were excluded. Preliminary studies showed that sequential distention-effect curves could be constructed, the second and third of which were highly reproducible (fig 2). In all subsequent experiments, the first distention-effect curve acted as a primer, the second as control, and the third curve was constructed following drug administration.

The 5-HT₃ receptor antagonist alosetron (1–100 µg/kg) inhibited the depressor response to colorectal distention in a dose related manner (fig 3). The response to 1.5 ml CRD was significantly inhibited at doses of 3–100 µg/kg ($p < 0.05$), giving an ID₅₀ of 3.0 µg/kg (0.4–9.3). At 10 µg/kg, alosetron reduced the response to 1.5 ml CRD to 3.3 (4.4) mm Hg compared with 21.8 (1.7) mm Hg control response ($p < 0.05$, $n = 5$). There was no further inhibition at doses up to 100 µg/kg (4.2 (2.4) mm Hg compared with 22.9 (2.3) mm Hg control response; $p < 0.05$, $n = 6$). Reduction of the response to 2.5 ml distention was greatest at 100 µg/kg (15.4 (6.1) mm Hg versus 27.1 (2.1) mm Hg control response; $p < 0.05$, $n = 6$). Alosetron had no effect on basal blood pressure (112.4 (6.8) mm Hg at 100 µg/kg versus 108.3 (6.1) mm Hg in control animals; $n = 6$).

FOS EXPRESSION

Repetitive CRD significantly increased bilateral expression of Fos-LI compared with sham distended animals (from 49 (24) to 1246 (146); $p < 0.05$, $n = 4–5$). This expression was located in discrete areas of the spinal grey mat-

Figure 5 Representative bitmap images illustrating distribution of Fos-like (Fos-LI) immunoreactivity in all treatment groups: (A) sham distended; (B) control colorectal distention (CRD); (C) CRD/alosetron, 30 µg/kg; (D) CRD/alosetron 100 µg/kg. Horizontal scale bar, 150 µm; arrows indicate examples of Fos-LI nuclei.

ter (fig 1): Fos-LI nuclei were located in superficial laminae I and II of the spinal cord (area 1, 27.6% of total), lateral laminae V and VI, including the intermediolateral horn (area 3, 31.3%), and the area surrounding the central canal (medial lamina VII and X; area 4, 30.2%). There were fewer Fos-LI nuclei in laminae III and IV (area 2, 10.9%), and staining in the ventral horn region of areas 3 and 4 was relatively sparse. In sham distended animals, total numbers of Fos-LI were too low to assess differences in regional distribution.

In animals pretreated with 100 µg/kg alosetron, total numbers of Fos-LI nuclei were significantly reduced (479.8 (122); $p < 0.05$, $n = 5$). At a lower dose (30 µg/kg), alosetron did not significantly reduce the total number of Fos-LI nuclei (993 (89), $n = 5$). Regionally, alosetron inhibited Fos-LI in specific areas of the spinal cord (see fig 4), with reductions of 56% in area 1, 63% in area 3, and 68% in area 4 (100 µg/kg, $p < 0.05$). There was no significant inhibition of Fos-LI in area 2. At 30 µg/kg, alosetron did not significantly reduce numbers of Fos-LI nuclei in any region, although there was a reduction of 35% in area 1. Figure 5 shows the distribution of Fos-LI nuclei in control and drug treated animals.

Discussion

We have shown that responses to CRD using two experimental paradigms are blocked by the 5-HT₃ receptor antagonist alosetron. In the pentobarbitone anaesthetised rat, noxious CRD elicits reproducible depressor responses, consistent with previous studies in both the small and large intestine.^{13–15} We have also shown that reproducible distention-effect curves obtained in this study can be used to assess drug effects. Of the animals tested, 74% displayed a vigorous depressor response to CRD, which is similar to previous findings.^{15–27} In the present study, the response parameters were somewhat dependent on the depth of anaesthesia. In urethane anaesthetised rats, however, where such reflexes are reported to be unaffected by anaesthetic levels, a similar proportion of animals do not display a depressor response to CRD,²⁷ thus levels of anaesthetic probably do not account for the majority of non-responders in the present study.

Alosetron is a potent and selective 5-HT₃ receptor antagonist, with a duration of action of several hours in the rat.^{29–32} It potently inhibited the depressor response to CRD, with an ID₅₀ of 3 µg/kg. The 1.5 ml distention volume at which the ID₅₀ is calculated was chosen as it produces a submaximal vasomotor response, of a similar magnitude to that evoked by 60–80 mm Hg barostat inflation (unpublished observations), and thus is well above the nociceptive threshold of approximately 30 mm Hg. Therefore the effects of alosetron at this distention volume are likely to be antinociceptive. In a similar study, the 5-HT₃ receptor antagonists ondansetron, tropisetron, and granisetron were shown to be approximately equipotent at inhibiting the depressor response to CRD.²⁸ They were 5–10 fold less potent than alosetron in the present study; bell shaped

dose-response relations obtained with certain 5-HT₃ receptor antagonists may, however, result in underestimation of their potency.²⁸ Alosetron did not display a bell shaped dose-response relation in this study, with stable inhibitory effects between 10 and 100 µg/kg. In other studies, systemic 5-HT₃ receptor antagonists block the vasomotor response to distention of the duodenum and colorectum^{27–33}; these data are therefore consistent with previous findings. Continuous monitoring of intraballoon pressure allowed the calculation of colorectal compliance from pressure-volume relations. Alosetron did not seem to affect colorectal compliance significantly in this study (unpublished observations), although this method may not be as sensitive as a barostat for detecting very small changes, as alosetron has been shown to increase compliance in studies in patients with IBS.^{6–8} Any such effects of alosetron on compliance in the present study would not be sufficient to account for its effect on the vasomotor response to CRD.

Noxious CRD also induced expression of the proto-oncogene *c-fos* in the lumbosacral spinal cord of urethane anaesthetised rats. Fos-LI nuclei were found bilaterally, mainly in laminae I, II, lateral V and VI, VII and X. A similar distribution pattern has been noted previously,^{18–24} which correlates with the termination sites of pelvic nerve afferents.^{34–35} The number of Fos-LI nuclei in the present study was lower than that reported in other studies, with 1246 (146) Fos-LI nuclei in 12 sections across the L6–S1 border, compared with over 300/section.²⁴ This difference may be explained by use of urethane anaesthesia in the present study, compared with halothane sedation in previous studies.

Alosetron (100 µg/kg) significantly reduced total numbers of Fos-LI in response to repetitive CRD, which was evident in both superficial (I, II) and deeper (V–VII, X) laminae. The dose of alosetron required was higher than that needed to inhibit the depressor response to CRD. There may be several explanations for this. Differences in balloon size and inflation procedure (constant pressure versus constant volume, different frequency, and intensity of stimulation) may have affected the apparent potency of alosetron. Following fixed volume inflation, a reduction in intraballoon pressure was sometimes apparent during the inflation period, which may result in reduced afferent stimulation. In contrast, a larger balloon, at constant pressure will recruit more afferent fibres and thus elicit a stronger response due to summation, and therefore be more difficult to inhibit. Furthermore, the repeated CRD paradigm has been reported to produce colonic inflammation,²⁴ which may result in altered mechanisms of nociceptive neurotransmission. Alosetron may also have subtle effects on compliance in the fixed volume experiment (see above), or may differentially affect afferent neurones mediating phasic and tonic components of the response. An alternative explanation may be that in order to see a reduction of the numbers of Fos-LI nuclei, the *c-fos* expression must be totally blocked. Gradations of

staining (amount of Fos-like protein) certainly do occur, but were not examined in the present study. This may also explain the steep dose-response curve obtained with alosetron, with a profound effect at 100 µg/kg, but no effect at 30 µg/kg. Different anaesthetics were used for the two experimental procedures, but it is unlikely that this had a major impact on the apparent efficacy of alosetron.

Induction of *c-fos* is thought to be largely indicative of c-fibre afferent activation, although Fos-LI occurs in response to both noxious and innocuous visceral^{24,36} and joint³⁷ stimulation. The majority of afferents innervating the colon are c-fibres, most of which show a graded response to increasing stimulus intensity. Therefore, inhibition of Fos-LI in this model does not necessarily represent inhibition of nociceptive pathways. Traub *et al* however, have reported that the opiate analgesics, morphine and tramadol, reduce CRD evoked spinal Fos-LI in both superficial and deep laminae.²⁶ Their study provides some evidence that a significant proportion of the CRD evoked Fos-LI results from noxious stimulation of these dorsal horn neurones.

5-HT₃ receptor protein and mRNA are widely distributed throughout the brain,^{39,40} spinal cord,^{39,41,42} and dorsal root ganglion neurones.⁴³ A large proportion of the spinal receptors are located on the central terminals of afferent neurones, many of which are capsaicin sensitive.⁴⁴ The present finding that deep as well as superficial laminar expression of *c-fos* was suppressed by alosetron, is not inconsistent with these data. Visceral afferent neurones have collaterals extending into deep as well as superficial laminae, although these neurones comprise a small proportion of the total number of afferents entering the spinal cord. Furthermore, many dorsal horn neurones in deeper laminae receive indirect input from superficial neurones; either these interneurons or the afferents terminating onto them may express 5-HT₃ receptors. Further evidence to support a role for 5-HT₃ receptors in nociceptive processing includes the inhibition, by granisetron, of CRD induced *c-fos* immunoreactivity in the nucleus of the solitary tract,⁴⁵ and the reduction of *c-fos* immunoreactivity in the trigeminal nucleus by 5-HT₃ receptor antagonists following noxious chemical stimulation of the rat nasal mucosa.⁴⁶ 5-HT₃ receptors are also found within the enteric nervous system of the gut, and are known to regulate gastrointestinal motility. Alosetron has been reported to normalise gut transit following sensitisation with egg albumin in rats,⁴⁷ and to increase colonic compliance in patients with IBS.^{6,8} Cramer and Rademaker,⁴⁸ however, have suggested that the site of action against distention evoked reflexes is not within the peripheral organ, as the 5-HT₃ receptor antagonist ICS 205 930 inhibits the depressor response to ileal distention, but has no effect on the concurrent increased firing in afferent dorsal root filaments. It is also worth noting that on vagal afferents innervating the stomach and small intestine, 5-HT₃ receptors are associated with mucosal chemoreceptors rather than

mechanoreceptors responsive to distention.⁴⁹ Alosetron has also been reported to inhibit the vasomotor response to CRD in dogs following intracerebroventricular injection, suggesting a central site of action.⁵⁰

In summary, these studies show that alosetron modulates visceral nociceptive neurotransmission in the rat, illustrated by a potent inhibition of the reflex depressor response to colorectal distention, and a reduction in numbers of Fos-LI nuclei in the spinal cord following repeated CRD. There is considerable anatomical and functional data to support a role for 5-HT₃ receptors in visceral nociceptive processing. The site(s) of action of alosetron were not established in the present study, but could be at the level of the enteric or primary sensory neurone, or via spinal or supraspinal neuronal circuits concerned with the modulation of nociceptive transmission. Based on these data, in addition to recent studies indicating that alosetron decreases symptoms of abdominal pain in patients with irritable bowel syndrome,^{5,7} alosetron may be of potential use in the treatment of visceral pain conditions.

- 1 Lemann M, Dederding J P, Flourie B, *et al*. Abnormal perception of visceral pain in response to gastric distention in chronic idiopathic dyspepsia. *Dig Dis Sci* 1991;**36**:1249–54.
- 2 Lipkin M, Sleisenger MH. Studies of visceral pain, measurements of stimulus intensity and duration associated with the onset of pain in esophagus, ileum and colon. *J Clin Invest* 1957;**37**:28–34.
- 3 Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. *Gut* 1973;**14**:125–32.
- 4 Mertz H, Naliboff B, Munkata J, *et al*. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. *Gastroenterology* 1995;**109**:40–52.
- 5 Bardhan K, Bodemar G, Geldof H, *et al*. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome [abstract]. *Gastroenterology* 1996;**110**:A630.
- 6 Delvaux M, Louvel D, Mamet JP, *et al*. Effect of alosetron on colonic sensitivity in patients with irritable bowel syndrome [abstract]. *Gastroenterology* 1996;**110**:A665.
- 7 Northcutt AR, Camilleri M, Mayer EA, *et al*. Alosetron, a 5-HT₃ antagonist, is effective in the treatment of female irritable bowel syndrome patients [abstract]. *Gastroenterology* 1998;**114**:A812.
- 8 Delvaux M, Louvel D, Mamet JP, *et al*. Effect of alosetron on colonic distension in patients with irritable bowel syndrome. *Aliment Pharmacol Ther* 1998;**12**:849–55.
- 9 Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-HT₃ receptor antagonist, in patients with irritable bowel syndrome. *Aliment Pharmacol Ther* 1993;**7**:175–80.
- 10 Maxton DG, Haigh CG, Whorwell PJ. 5-HT₃ antagonism: a role in irritable bowel syndrome and non-ulcer dyspepsia? [abstract]. *Gut* 1991;**32**:A1228.
- 11 Steadman CJ, Talley NJ, Phillips SF, *et al*. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome—a pilot study. *Mayo Clin Proc* 1992;**67**:732–8.
- 12 Crowley RT. Reflex modification of respiration by intestinal distension. *Am J Physiol* 1941;**133**:253–4.
- 13 Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterisation of pseudoeffective reflexes in the rat. *Brain Res* 1988;**450**:153–69.
- 14 Ness TJ, Gebhart GF. Visceral pain: a review of experimental studies. *Pain* 1990;**41**:167–234.
- 15 Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. *N-S Arch Pharmacol* 1982;**321**:116–22.
- 16 Skofitsch G, Lembeck F. Visceral pain mediated by capsaicin sensitive neurones. *N-S Arch Pharmacol* 1982;**313**:R32.
- 17 Menetrey D, Gannon A, Levine JD, *et al*. Expression of *c-fos* protein in interneurons and projection neurons of the rat spinal cord in response to noxious somatic, articular and visceral stimulation. *J Comp Neurol* 1989;**285**:177–95.
- 18 Lanteri-Minet M, Isnardon P, dePommery J, *et al*. Spinal and hindbrain structures involved in viscerosensation and viscerosensation as revealed by the expression of Fos, Jun and Krox-24 proteins. *Neuroscience* 1993;**55**:737–53.
- 19 Jin GR, Rao ZR, Shi JW. Visceral noxious stimulation induced expression of Fos protein in medullary catecholaminergic neurons projecting to nucleus accumbens in the rat: a study with triple labeling method of HRP tracing

- combined with Fos and TH immunohistochemistry. *Brain Res* 1994;648:196–202.
- 20 Cruz F, Avelino A, Coimbra A. Desensitisation follows excitation of bladder primary afferents by intravesical capsaicin, as shown by c-fos activation in the rat spinal cord. *Pain* 1996;64:553–7.
  - 21 Clement CI, Keay KA, Owler BK, et al. Common patterns of increased and decreased fos expression in midbrain and pons evoked by noxious deep somatic and noxious visceral manipulations. *J Comp Neurol* 1996;366:495–515.
  - 22 Fitch GK, Weiss ML. Ureteral ligation induces Fos expression in the dorsal horn. *Brain Res* 1996;723:199–205.
  - 23 Martinez V, Wang LX, Mayer E, et al. Proximal colon distension increases fos expression in the lumbosacral spinal cord and activates sacral parasympathetic NADPH-positive neurons in rats. *J Comp Neurol* 1998;390:311–21.
  - 24 Traub RJ, Pechman P, Iadarola MJ, et al. Fos-like proteins in the lumbosacral spinal cord following noxious and non noxious colorectal distension in the rat. *Pain* 1992;49:393–403.
  - 25 Birder LA, Roppolo JR, Iadarola MJ, et al. Electrical stimulation of visceral afferent pathways in the pelvic nerve increases c-fos in the rat lumbosacral spinal cord. *Neurosci Lett* 1991;129:193–6.
  - 26 Traub RJ, Stitt S, Gebhart GF. Attenuation of c-Fos expression in the rat lumbosacral spinal cord by morphine or tramadol following noxious colorectal distension. *Brain Res* 1995;701:175–82.
  - 27 Moss HE, Sanger GJ. The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distension. *Br J Pharmacol* 1990;100:497–501.
  - 28 Scott CM, Green A, Gale JD, et al. The effect of 5-HT₃ receptor antagonists on the depressor response to colorectal distension in the anaesthetised rat. *Br J Pharmacol* 1994;112:101P.
  - 29 Kilpatrick GJ, Hagan RM, Butler A, et al. GR68755, a potent and selective antagonist of 5-HT₃ receptors. *Br J Pharmacol* 1991;104:259P.
  - 30 Scott CM, Grundy D, Boissonade FM, et al. Alosetron inhibits the colorectal distension-evoked depressor response and spinal c-fos expression in the anaesthetised rat [abstract]. *Gastroenterology* 1997;112:A822.
  - 31 Boissonade FM, Sharkey KA, Davison JS. Fos expression in ferret dorsal vagal complex after peripheral emetic stimuli. *Am J Physiol* 1994;35:R1118–26.
  - 32 Clayton NM, Sargent R, Butler A, et al. The pharmacological properties of the novel selective 5-HT₃ receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. *Neurogastroenterol Motil* 1999;11:207–17.
  - 33 Banner SE, Carter M, Sanger GJ. 5-Hydroxytryptamine 3 receptor antagonism modulates a noxious visceral pseudoaffactive reflex. *Neuropharmacology* 1995;34:263–7.
  - 34 Nadelhaft I, Booth AM. The location and morphology of preganglionic neurons and the distribution of visceral afferents from the rat pelvic nerve: a horseradish peroxidase study. *J Comp Neurol* 1984;226:238–45.
  - 35 DeGroat WC. Neuropeptides in pelvic afferent pathways. *Experientia* 1986;43:801–13.
  - 36 Birder LA, DeGroat WC. Induction of c-fos expression in spinal neurons by nociceptive and non nociceptive stimulation of LUT. *Am J Physiol* 1993;34:R326–33.
  - 37 Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurones following sensory stimulation. *Nature* 1987;328:632–4.
  - 38 Sengupta JN, Gebhart GF. Characterization of mechanosensitive pelvic nerve afferent fibres innervating the colon of the rat. *J Neurophysiol* 1994;71:2046–60.
  - 39 Laporte AM, Koscielniak T, Ponchant M, et al. Quantitative autoradiographic mapping of 5-HT₃ receptors in the rat CNS using (¹²⁵I)iodo-zacopride and (³H)zacopride as radioligands. *Synapse* 1992;10:271–81.
  - 40 Tecott LH, Maricq AV, Julius D. Nervous system distribution of the serotonin 5-HT₃ receptor mRNA. *Proc Natl Acad Sci USA* 1993;90:1430–4.
  - 41 Kia HK, Miquel MC, McKernan RM, et al. Localization of 5-HT₃ receptors in the rat spinal cord: immunohistochemistry and in situ hybridisation. *Neuroreport* 1995;6:257–61.
  - 42 Laporte AM, Fattaccini CM, Lombard MC, et al. Effects of dorsal rhizotomy and selective lesion of serotonergic and noradrenergic systems on 5-HT_{1A}, 5-HT_{1B} and 5-HT₃ receptors in the rat spinal cord. *J Neural Transm Gen Sect* 1995;100:207–23.
  - 43 Pierce PA, Xie GX, Levine JD, et al. 5-hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. *Neuroscience* 1996;70:553–9.
  - 44 Hamon M, Gallissot MC, Menard F, et al. 5-HT₃ receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. *Eur J Pharmacol* 1989;164:315–22.
  - 45 Monnikes H, König M, Arnold R. Colonic distension-induced c-fos expression in the nucleus tractus solitarius (NTS) is diminished by the 5-HT₃ receptor antagonist granisetron [abstract]. *Neurogastroenterol Motil* 1995;7:A62.
  - 46 Ebersberger A, Anton F, Tolle TR, et al. Morphine, 5-HT₂ and 5-HT₃ receptor antagonists reduce c-fos expression in the trigeminal nuclear complex following noxious chemical stimulation of the rat nasal mucosa. *Brain Res* 1995;676:336–42.
  - 47 Clayton NM, Gale JD, Bountra C, et al. Normalisation of perturbed small bowel transit by alosetron, a 5-HT₃ receptor antagonist in the rat. *Dig Dis Sci* 1996;41:1903.
  - 48 Cramer WCM, Rademaker B. 5-HT₃ receptors and visceral nociception: involvement and localisation. *Dig Dis Sci* 1989;44:A-4.
  - 49 Eastwood C, Hillsley K, Grundy D. Sub-populations of small intestinal mucosal afferents identified by their sensitivity to CCK, 5-HT and opiates. *Neurogastroenterol Motil* 1995;7:256.
  - 50 Miura M, Lawson C, Clary EM, et al. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT₃ receptor antagonist. *Dig Dis Sci* 1999;44:20–4.